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The extracellular matrix of articular cartilage consists of a
large number of tissue-specific macromolecules including type
II, IX, and XI collagens and the large aggregating proteoglycan,
aggrecan (1). These extracellular matrix components are produced by chondrocytes, highly differentiated cells responsible
for the maintenance of the structural integrity of the tissue
through a precisely regulated balance between the synthesis
and the degradation of these cartilage-specific macromolecules.
The biosynthetic program of chondrocytes is determined by the
highly conserved expression of a set of cartilage-specific genes
(type II, IX, and XI collagens and the proteoglycan aggrecan),
which is maintained during complex biological processes such
as cartilage development, differentiation, and repair (2).
Most of the studies that examined the stability of the chondrocyte phenotype have consistently shown that culture of
these cells in monolayers on plastic substrata for prolonged
periods or upon repeated passages leads to the loss of their
spherical shape and to the acquisition of an elongated fibroblast-like morphology (3–10). These morphologic alterations
are accompanied by profound biochemical changes including
the loss of production of cartilage-specific macromolecules, initiation of synthesis of the interstitial collagens (types I, III, and
V), and an increase in the synthesis of fibroblast-type proteoglycans (versican) at the expense of aggrecan (3–12). The chondrocyte-specific phenotype can be reexpressed when these cells
are cultured in agarose or alginate matrices (6, 10, 11) or, as
shown in our recent studies, by culture on a hydrogel (12).
Few studies have been performed to characterize the transcriptional activity and regulation of the promoter of the cartilage-specific type II procollagen gene (COL2A1) despite the
crucial role that its encoded product plays in the maintenance
of the structure and function of articular cartilage. Structural
and functional analyses of the promoter regions of COL2A1
have revealed multiple putative regulatory elements (13–17).
Electrophoretic mobility shift assays employing bp 2977 to
230 of the COL2A1 promoter and nuclear extracts from chick
embryonic chondrocytes indicated the involvement of an Sp1like factor in the cartilage-specific expression of the gene, since
the addition of anti-Sp1 antibodies to the binding reaction
caused a supershift of the DNA-protein complex (16). Moreover,
short mutations in the Sp1 binding sites abolished the formation of the DNA-protein complex (16). DNase I footprint analysis indicated that a sequence between bp 2132 and 2101 of
the COL2A1 promoter bound nuclear proteins isolated from
chick embryonic chondrocytes (16). Western/Southwestern
analyses showed that a protein complex that included Sp1
could bind to the COL2A1 promoter and enhancer under nondenaturing conditions and was dissociated under denaturing
conditions. These results suggested the formation of a DNA
loop structure between the COL2A1 promoter and enhancer
that is mediated by nuclear proteins (16) and clearly indicated
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We have detected DNA binding activity for a synthetic
oligonucleotide containing an Sp1 consensus sequence
in nuclear extracts from human chondrocytes. Changes
in the levels of Sp1 oligonucleotide binding activity
were examined in nuclear extracts from freshly isolated
human chondrocytes, from chondrocytes that had been
cultured under conditions that allowed the maintenance of a chondrocyte-specific phenotype on plastic
dishes coated with the hydrogel poly(2-hydroxyethyl
methacrylate), and from chondrocytes induced to dedifferentiate into fibroblast-like cells by passage in
monolayer culture on plastic substrata. It was observed
that Sp1 binding was 2–3-fold greater in nuclear extracts
from dedifferentiated chondrocytes than in nuclear extracts from either freshly isolated chondrocytes or from
cells cultured in suspension. The Sp1 binding activity
was specific, since it was competed by unlabeled Sp1 but
not by AP1 or AP2. The addition of a polyclonal antibody
against Sp1 to nuclear extracts from freshly isolated
chondrocytes or to extracts isolated from chondrocytes
cultured in monolayer decreased the binding of Sp1 by
;85%. However, when the same experiment was carried
out with nuclear extracts prepared from cells cultured
on poly(2-hydroxyethyl methacrylate)-coated plates,
only a very slight inhibition of Sp1 binding was observed. When fragments of the COL2A1 promoter containing putative Sp1 binding sites amplified by polymerase chain reaction were examined, it was found that
the amounts of DNA-protein complex formed with nuclear extracts from dedifferentiated chondrocytes were
2–3-fold greater than the amounts formed with nuclear
extracts from freshly isolated chondrocytes or from cells
cultured in suspension. Quantitation of DNA binding
activity by titration experiments demonstrated that
nuclear extracts from fibroblast-like cells contained
approximately 2-fold greater Sp-1 specific binding activity than nuclear extracts from chondrocytes. The
direct role of Sp1 in type II collagen gene transcription
was demonstrated by co-transfection experiments of
COL2A1 promoter-CAT constructs in Drosophila
Schneider line L2 cells that lack Sp1 homologs. This is
the first demonstration of Sp1 binding activity in human chondrocytes and of differences in Sp1 DNA binding activity between differentiated and dedifferentiated chondrocytes.

Sp1 and Chondrocyte Dedifferentiation
the importance of transacting factors in the regulation of expression of COL2A1. However, studies of the changes in DNAbinding proteins that may occur during chondrocyte dedifferentiation have not been examined in detail, although one study
showed that chondrocyte dedifferentiation was associated with
the induction of nuclear factor binding activity for an AP-1 site
and with a concomitant activation of pro-a1(I) collagen gene
transcription (18). In this study we investigated the changes in
the levels and activity of the transcriptional factor Sp1 occurring during the process of chondrocyte dedifferentiation.
EXPERIMENTAL PROCEDURES

1
The abbreviations used are: polyHEMA, poly(2-hydroxyethyl methacrylate); DTT, dithiothreitol; PCR, polymerase chain reaction; CAT,
chloramphenicol acetyltransferase; bp, base pair(s).

phate buffer, pH 7.4, 137 mM NaCl, and 2.7 mM KCl). The resulting cell
pellets were resuspended in a hypotonic buffer (10 mM HEPES, pH 7.9,
at 4 °C, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM phenylmethylsulfonic fluoride, and 0.5 mM DTT) approximately 5 times the packed cell volume
and centrifuged at 3000 rpm for 5 min. The pellet was resuspended in
3 times the original packed cell volume in hypotonic buffer and incubated for 10 min on ice. Next, the cells were homogenized slowly with 10
strokes in a Dounce homogenizer, and the nuclei were collected by
centrifugation at 4000 rpm for 15 min. The nuclei were resuspended in
one-half packed nuclear volume of low salt buffer (20 mM HEPES, pH
7.9, at 4 °C, 25% glycerol, 1.5 mM MgCl2, 0.02 M KCl, 0.2 mM EDTA, 0.2
mM phenylmethylsulfonic fluoride, 0.5 mM DTT). This was followed by
dropwise addition with continuous stirring of one-half packed nuclear
volume of high salt buffer (20 mM HEPES, pH 7.9, at 4 °C, 25% glycerol,
1.5 mM MgCl2, 1.2 M KCl, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonic
fluoride, 0.5 mM DTT) and centrifugation at 14,500 rpm for 30 min. The
supernatant was next dialyzed against approximately 50 volumes of
dialysis buffer (20 mM HEPES, pH 7.9, at 4 °C, 20% glycerol, 100 mM
KCl, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonic fluoride, 0.5 mM DTT)
for 5 h and then stored in aliquots at 270 °C. The resulting nuclear
extracts were utilized for electrophoretic mobility shift analysis.
Amplification of COL2A1 Promoter by PCR—The reaction was carried out as follows. 150 ng of a1(II) procollagen minigene, which contains the entire COL2A1 promoter region (24), was utilized as a template and was amplified with 10 pmol of each primer set (P1/P2, P3/P4,
P5/P6, P7/P8; see Fig. 9) under the following conditions: 95 °C for 30 s
and 60 °C for 1 min for 40 cycles followed by a final extension at 72 °C
for 7 min in a Gene Amp 480 thermocycler (Perkin-Elmer).
Electrophoretic Mobility Shift Analysis of DNA-binding Proteins—
Electrophoretic mobility shift analyses were performed according to the
procedure of Garner and Revzia (25), as described previously (26). The
PCR products containing specific regions of COL2A1 prepared as described above were end-labeled by kinasing the 59-primer with T4
polynucleotide kinase and [g-32P]ATP and then carrying out the PCR
reaction. The binding reaction was 20 mM Tris, pH 7.5, 10 mM sodium
acetate, 0.5 mM EDTA, 5% glycerol, and 10 –15 mg of nuclear extract in
a final volume of 20 ml. Next, 3–5 3 103 cpm of end-labeled probe was
added, and the incubation was carried out for 1 h at room temperature.
DNA-protein complexes were separated by electrophoresis on 5% polyacrylamide gels in 40 mM Tris acetate, 1 mM EDTA buffer and visualized by autoradiography.
Determination of the Specificity of Binding—The specificity of binding of putative regulatory elements within the PCR fragments was
confirmed by competition with unlabeled specific oligonucleotides (consensus Sp1, AP1, and AP2 oligonucleotides, Santa Cruz Biotechnology,
Santabury, CA). Once the binding was determined to be specific, an
anti-Sp1 antibody (Santa Cruz Biotechnology) was utilized. Electrophoretic mobility shift assays were carried out as outlined above. Nuclear extracts were preincubated with increasing concentrations of the
anti-Sp1 antibody for 60 min at 20 °C before the binding reaction was
carried out.
Quantitation of Sp1-binding Proteins in Chondrocytes—The level of
Sp1-binding protein in nuclear extracts of chondrocytes was quantitated by protein titration experiments analyzed by gel shift analysis as
described by Riggs et al. (27). One set of binding reactions contained a
constant amount of labeled Sp1 and an increasing concentration of
protein. The amounts of bound and free probe were quantitated by
scintillation counting of excised regions of the gel. In the plateau region
with excess protein, it was possible to determine the amount of protein
required to reach equilibrium with the DNA probe. This reaction allowed determination of the proportion of DNA probe bound to protein,
since under some conditions binding of probe is not complete even if
there is excess protein present. The second set of titration experiments
was performed under identical conditions except that the amount of
protein determined from the first set of binding reactions was maintained constant while the amount of Sp1 oligonucleotide was increased.
At plateau, all of the protein would be expected to be saturated with the
Sp1 oligonucleotide. The counts per minute at plateau correspond to the
amount of probe required to bind all of the active protein involved in
DNA binding. By comparing the amount of probe in the DNA-protein
complex to a set of standard dilutions of free probe included on a gel
electrophoresed in parallel, the number of moles of protein in the
reaction can be calculated assuming a one-to-one binding, since the
specific activity and the molarity of probe was known.
Drosophilia Schneider Line 2 Cell Culture and Transfections—Drosophila Schneider line 2 cells (28), which lack Sp1 homologs, were
cultured in Schneider Drosophila medium (Life Technologies, Inc.,
Rockville, MD) supplemented with 12% heat-inactivated serum and 1%
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Isolation and Culture of Human Chondrocytes—Human fetal epiphyseal cartilage was removed under sterile conditions from femoral
heads, knee condyles, and tibial plateaus from spontaneous abortions.
The tissues were obtained from the International Institute for the
Advancement of Medicine (Philadelphia, PA), following protocols reviewed and approved by the National Institutes of Health and the
Institutional Review Committee in accordance with the National Organ
Transplant Act and the Pennsylvania Organ Transplant Act. To remove
adherent fibrous tissues, the cartilage was incubated in Hanks’ medium
containing trypsin and bacterial collagenase (2 mg/ml each) for 1 h at
37 °C. The medium was discarded, and the tissue fragments were
minced and digested overnight at 37 °C in Dulbecco’s minimum essential medium with 4.5 g/liter glucose containing 10% fetal bovine serum
and 0.5 mg/ml bacterial collagenase. The cells released by the enzymatic digestion were filtered through a nylon membrane into a vessel
containing fresh Dulbecco’s minimum essential medium and 10% fetal
bovine serum. The cells were collected by centrifugation at 250 3 g for
5 min, resuspended, and washed four times with collagenase-free medium. The average yield was 3.0 6 0.4 3 108 chondrocytes/g, wet
weight, of cartilage.
The isolated chondrocytes were cultured at a density of 5 3 106 cells
in 60-mm plastic dishes previously coated with 0.9 ml of a 10% (v/v) of
polyHEMA1 (19, 20) (PolySciences Inc. Malvern, PA) following a procedure modified from that described by Folkman and Moscona (21) as
described previously (12). For coating the culture dishes with polyHEMA, 0.9 ml of a 10% (v/v) solution of polyHEMA in 95% ethanol was
layered onto 60-mm Falcon bacterial culture dishes and was allowed to
dry overnight under a tissue culture hood. The polyHEMA-coated
dishes were sterilized by exposure to bactericidal ultraviolet light for 30
min. The culture medium employed for these studies was Dulbecco’s
minimum essential medium containing 4.5 g/liter glucose, 10% fetal
bovine serum, 1000 units/ml penicillin, 1 mg/ml streptomycin, 2 mM
glutamine, 1% vitamin supplements, 2.5 mg/ml fungizone, and 50 mg/ml
ascorbic acid. The medium was replaced every 3– 4 days. The differentiated chondrocytes were those cultured on poly(HEMA) dishes. The
dedifferentiated chondrocytes were those that were plated at a density
of 2.5 3 106 cells on T75 flasks so that they would grow as attached cells
in the same medium as that used for growing cells on poly(HEMA)coated dishes and passaged twice at 20-day intervals.
Western Blot Analysis—For Western blot analysis, freshly isolated
chondrocytes, chondrocytes that had been cultured on poly(HEMA)coated plates, and fibroblast-like chondrocytes that were passaged on
plastic were utilized. The cells were suspended and then centrifuged at
3,000 rpm for 5 min and washed twice with phosphate-buffered saline.
They were heated to 100 °C for 5 min in 1% SDS, 50 mM DTT, and 1%
(v/v) glycerol, and the cell-associated proteins were separated by electrophoresis in 6% polyacrylamide gels on a minigel apparatus at 125 V
for 90 min. The proteins were electroblotted at 40 V for 90 min from the
polyacrylamide gel onto a supported nitrocellulose membrane, and the
transferred proteins were reacted for 30 min with a 1:500 dilution (v/v)
of SJ 441 antibody, which is a polyclonal antibody specific for the
COOH-terminal telopeptide of human type II collagen (22), or with an
anti-type I human collagen polyclonal antibody purchased from Southern Biotechnology Associates, Inc. (Birmingham, AL). The proteins on
the filter were detected utilizing the ECL Western blotting detection
reagent (Amersham Corp.).
Preparation of Nuclear Extracts—Chondrocyte nuclear extracts were
prepared according to the procedures of Dignam et al. (23). The cells
were pooled and washed in phosphate-buffered saline (10 mM phos-
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FIG. 2. Western blot analysis of collagens synthesized by cultured human fetal chondrocytes. The cell-associated proteins synthesized by chondrocytes cultured under the various conditions were
extracted as described under “Experimental Procedures” and subjected
to Western blot analysis utilizing either a polyclonal antibody specific
for the type II procollagen telopeptide (22) or a polyclonal antibody
specific for type I collagen. Lanes 1 and 4, freshly isolated chondrocytes.
Lanes 2 and 5, chondrocytes cultured on polyHEMA. Lanes 3 and 6,
chondrocytes dedifferentiated into fibroblast-like cells following passage on plastic. The position of migration of the a1 and a2 chains of type
I collagen is shown.

penicillin/streptomycin at 25 °C. The cells were seeded at a density of
1 3 106 cells/60-mm dish 16 h prior to transfection. Transient transfections were performed by the calcium phosphate precipitation method
with the Profection mammalian transfection system (Promega, Madison, WI). The transfections were performed using 100 mg of either
pPacSp1 plasmid, which contains a 2.1-kilobase pair Sp1 cDNA insert
or the insertless plasmid pPac0 (29) and 5 mg of either E/0.7-CAT, a
human COL2A1 promoter construct spanning bp 2577 to 163 linked to
the CAT reporter gene or E/0.2-CAT, a human COL2A1 promoter construct spanning bp 2131 to 163 linked to the CAT reporter gene. All of
the reactions contained 0.5 mg of phsp82LacZ, a plasmid containing the
Drosophila heat shock protein 82 promoter fused to the lacZ gene to
correct for variations in transfection efficiencies. The transfected cells
were harvested following a 48-h incubation, and CAT activity was
determined from equal amounts of cell extracts as described previously
(26).
RESULTS

Detection of Sp1 Binding in Chondrocyte Nuclear Extracts—
Nuclear extracts were prepared from freshly isolated chondrocytes, from chondrocytes cultured on polyHEMA for 12 days
under conditions that allow the preservation of the cartilagespecific phenotype, and from chondrocytes that lost their phenotype and became morphologically fibroblast-like by passage
in monolayer culture on plastic for 40 days. The phase-contrast
morphology of the three cell types is shown in Fig. 1. Western
blot analysis of cell extracts isolated from the three different
cell types indicated that culture of chondrocytes on polyHEMA
allows preservation of the cartilage-specific phenotype as they
continue to express type II collagen and not type I collagen (Fig.
2). In contrast, culture and passage of chondrocytes in monolayer on plastic leads to loss of their chondrocyte-specific phenotype as these cells express markedly lower levels of type II
collagen and initiate production of large amounts of fibroblastspecific type I collagen (Fig. 2).
For detection of Sp1 binding activity, the consensus Sp1
oligonucleotide (59-ATTCGATCGGGGCGGGGCGAGC-39) was
radiolabeled and used as a probe in the binding assays. As
shown in Fig. 3, there was binding of nuclear proteins from
freshly isolated chondrocytes and from fibroblast-like cells to
consensus Sp1 oligonucleotide. However, the binding of nuclear
extracts from dedifferentiated chondrocytes to Sp1 was 2–3fold greater than the binding of nuclear extracts from freshly
isolated chondrocytes. The results obtained from chondrocytes
that were cultured on polyHEMA-coated plates in suspension

FIG. 3. Binding of nuclear extracts from freshly isolated chondrocytes and from fibroblast-like cells. Nuclear extracts were prepared from freshly isolated chondrocytes or from chondrocytes that
were allowed to become fibroblast-like by culture for 40 days on plastic
and were examined for binding to consensus Sp1 oligonucleotide and
competition analysis with unlabeled Sp1. The nuclear extracts were
preincubated with the indicated amounts of unlabeled consensus Sp1
oligonucleotide at room temperature for 30 min followed by the addition
of labeled consensus Sp1 oligonucleotide for 1 h at room temperature.

were similar to those obtained from freshly isolated chondrocytes (data not shown).
Specificity of Sp1 Binding—The binding of labeled Sp1 to
nuclear extracts from both chondrocytes and fibroblast-like
cells was competed away completely when a 10-fold excess of
unlabeled Sp1 was added (Fig. 3). However, when unlabeled
AP1 or AP2 was added to the reaction, the binding of labeled
Sp1 was not competed away, indicating that the DNA-protein
complexes were specific for Sp1 (Figs. 4 and 5). Moreover, when
the binding of recombinant Sp1 was carried out with the consensus Sp1 oligonucleotide, a DNA-protein complex of the same
size as that observed upon binding of Sp1 to chondrocyte or
fibroblast-like nuclear proteins was observed (not shown). The
DNA-protein complex formed between recombinant Sp1 and
consensus Sp1 oligonucleotide had the same pattern of migration as the complex formed by the consensus Sp1 oligonucleotide with nuclear proteins from either chondrocytes or fibroblast-like cells. The Sp1 binding with extracts from both
chondrocytes and fibroblast-like cells was enhanced by the
addition of increasing amounts of KCl as shown in Fig. 6.
Moreover, the addition of increasing amounts of EDTA inhibited the formation of the DNA-protein complex (Fig. 7). The
inhibition of Sp1 binding by EDTA was abrogated when MgCl2
was added to the binding reaction, and when equal concentrations of EDTA and MgCl2 were present (40 mM each) in the
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FIG. 1. Phase contrast micrographs of cultured human fetal
chondrocytes. The cells were isolated as described under “Experimental Procedures.” A, freshly isolated chondrocytes. B, freshly isolated
chondrocytes 12 days following plating on polyHEMA. C, freshly isolated chondrocytes passaged twice at 20-day intervals on plastic.
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FIG. 5. Competition analysis with unlabeled Sp1, AP-1, and
AP-2. Binding of nuclear extracts with 32P-labeled consensus Sp1 was
carried out in the presence of a 10-fold excess of unlabeled Sp1, AP-1, or
AP-2. The nuclear extracts were preincubated with unlabeled consensus Sp1, AP-1, or AP-2 at room temperature for 30 min followed by the
addition of labeled consensus Sp1 oligonucleotide for 1 h at room
temperature.

binding reaction no inhibition of Sp1 binding was observed. The
inhibition of Sp1 binding by EDTA was not abrogated by the
addition of ZnCl2. Thus, the formation of Sp1 protein complex
requires the presence of Mg21.
Effect of the Addition of a Polyclonal Sp1 Antibody to Nuclear
Extracts—When a polyclonal anti-Sp1 antibody was preincubated with the chondrocyte nuclear extracts prior to the binding reaction, only a weak inhibition of the protein-Sp1 complex
was observed even at an antibody concentration of 15 mg.
However, when 15 mg of anti-Sp1 was added to the fibroblastlike nuclear extract, greater than 80% inhibition of the DNAprotein complex was observed (Fig. 8).
Amplification of COL2A1 Promoter by PCR—As illustrated
in Fig. 9A, four consensus Sp1 binding sites (GGGCGG) at
nucleotides 280 to 275, 2115 to 2110, 2119 to 2114, and
2198 to 2193 have been identified in the human COL2A1
promoter. Three of these (at nucleotides 280, 2119, and 2198)
are found at identical locations in the human, mouse, and rat

FIG. 6. Effect of increasing concentrations of KCl on binding of
nuclear extracts isolated from chondrocytes and fibroblast-like
cells to consensus Sp1 oligonucleotide. Binding reactions were
performed as described under “Experimental Procedures.” The nuclear
protein utilized for each experiment was 15 mg for chondrocytes and 5
mg for fibroblast-like cells. The indicated concentrations of KCl were
present in each binding reaction.

FIG. 7. Effects of increasing concentrations of EDTA and
MgCl2 on binding of chondrocyte nuclear extracts to consensus
Sp1 oligonucleotide. The indicated amounts of EDTA and MgCl2
were present in the binding reaction that was performed as described
under “Experimental Procedures.”

COL2A1 promoters. The extremely high conservation of these
sequences coupled with the observation that the CCAAT box is
absent in the human COL2A1 promoter suggests that these
Sp1 sites may play a major role in determining the activity of
the COL2A1 promoter. We amplified the region encompassing
of the COL2A1 promoter nucleotides 2391 to 240 in four
fragments designated P1/P2, P3/P4, P5/P6, and P7/P8 as
shown in Fig. 9 (A and B).
Detection of Nuclear Proteins from Freshly Isolated Chondrocytes and from Chondrocytes Dedifferentiated into Fibroblastlike Cells That Bind to Sp1 Binding Sites in the COL2A1
Promoter—As shown in Fig. 10, we detected binding of chondrocyte nuclear proteins to COL2A1 promoter fragments spanning bp 2226 to 2148 (fragment P5/P6; Fig. 10, lane 1) and bp
2169 to 240 (fragment P7/P8; Fig. 10, lane 7) from the initiation of transcription site. Since these fragments contain putative Sp1 sites, we examined the effects of added unlabeled Sp1
to the binding reaction. The formation of DNA-protein com-
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FIG. 4. Competition analysis with unlabeled AP-1. Binding of
nuclear extracts with 32P-labeled consensus Sp1 was carried out in the
presence of increasing amounts of AP-1. The nuclear extracts were
preincubated with the indicated amounts of unlabeled consensus AP1
oligonucleotide at room temperature for 30 min followed by the addition
of labeled consensus Sp1 oligonucleotide for 1 h at room temperature.
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FIG. 9. PCR amplification of the region encompassing nucleotides 2391 to 240 of the COL2A1 promoter. Panel A, sequence of
the COL2A1 promoter showing the consensus regulatory sequences and
the position of the primers employed. The putative regulatory elements
are boxed. P, pyrimidine-rich sequence; E, enhancer core elements; S,
Sp1 binding sites; T, TATAAA box. Panel B, agarose gel electrophoresis
of the amplified PCR products utilizing the indicated primers.

plexes with nuclear proteins from human chondrocytes was
completely competed by a 10-fold excess of unlabeled Sp1,
indicating that the Sp1 sites on P5/P6 and P7/P8 are involved
in binding (Fig. 10, lanes 2 and 8). The DNA-protein complex
formed by each COL2A1 promoter fragment was also competed
by a 10-fold excess of corresponding unlabeled COL2A1 promoter fragment as shown in Fig. 10, lanes 3 and 9. In addition,
P5/P6 competed the complex formed with P7/P8 in nuclear
extracts isolated from chondrocytes and chondrocytes dediffer-

entiated into fibroblast-like cells (results not shown). Similar
results were observed when nuclear proteins were isolated
from chondrocytes dedifferentiated into fibroblast-like cells except that there was a 2–3-fold greater binding in nuclear extracts from dedifferentiated chondrocytes cultured in monolayer as compared with that from fresh chondrocytes (Fig. 10,
lanes 4, 5, 6, 10, 11, and 12).
Quantitation of Sp1-binding Proteins in Chondrocytes—The
amounts of nuclear proteins from chondrocyte and fibroblastlike cells that bind to the consensus Sp1 oligonucleotide were
quantitatively determined by DNA-binding protein titration
experiments. The first set of binding reactions contained a
constant amount of labeled Sp1 oligonucleotide (88 nM) and
increasing concentrations of nuclear protein. When the chondrocyte nuclear protein concentration was increased from 1 to
25 mg/reaction, an increase in the amount of DNA-protein
complex formed was detected (Fig. 11, A and B). Increasing the
concentration of nuclear proteins in the reaction above 20 mg/
reaction did not result in a further increase in binding, indicating that at this concentration equilibrium was reached with
the labeled Sp1 oligonucleotide. Therefore, in the next set of
reactions, the concentration of nuclear proteins was maintained constant at 20 mg/reaction, and the amount of Sp1
oligonucleotide was increased from 22 to 352 nM/reaction. As
shown in Fig. 11, C and D, the binding was essentially complete
at a concentration of 264 nM. Thus, at the plateau of 264 nM, all
of the DNA-binding protein was saturated with Sp1. Next, a set
of standard dilutions of the free oligonucleotide ranging from
22 to 352 nM was electrophoresed, and the radioactivity of the
free probe was determined (Fig. 11, E and F). Comparison of
the amount of oligonucleotide in the DNA-protein complex with
a set of standard dilutions of free oligonucleotide demonstrated
that 11.88 nM of chondrocyte nuclear protein was bound to the
Sp1 oligonucleotide in the reaction, assuming a one-to-one
binding of the probe and the Sp1 oligonucleotide. Similar experiments were performed with nuclear extracts isolated from
chondrocytes dedifferentiated into fibroblast-like cells. Since
the binding of 88 nM of Sp1 oligonucleotide was saturated at a
protein concentration of 20 mg (Fig. 11, A and B) in the next set
of reactions, 20 mg of protein was used per reaction, and the
concentration of Sp1 oligonucleotide was increased from 22 to
352 nM/reaction. As shown in Fig. 11, C and D, the binding was
essentially complete at a concentration of 264 nM, similar to
that observed for chondrocyte nuclear protein. Comparison of
the amount of oligonucleotide in the DNA protein complex to a
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FIG. 8. Effect of preincubation with specific anti-Sp1 antibody
on the binding of nuclear extracts isolated from chondrocytes
and fibroblast-like cells to Sp1 oligonucleotide. The nuclear extracts were preincubated with the indicated amounts of a polyclonal
anti-Sp1 antibody at room temperature for 30 min before the binding
reaction, which was performed as described under “Experimental
Procedures.”

FIG. 10. Binding of nuclear extracts from freshly isolated
chondrocytes and from chondrocytes dedifferentiated into fibroblast-like cells to PCR-amplified COL2A1 promoter fragments. 10 mg of each nuclear extract from freshly isolated chondrocytes
or from chondrocytes allowed to become fibroblast-like by culture on
plastic for 40 days was utilized and electrophoresed on a 6% polyacrylamide gel for DNA binding. The COL2A1 promoter fragments examined
were P5/P6 (bp 2226 to 2148, lanes 1– 6) and P7/P8 (bp 2169 to 240,
lanes 7–12). Lanes 1–3 and 7–9, binding with chondrocyte nuclear
protein; lanes 4 – 6 and 10 –12, binding with fibroblast-like nuclear
protein; lanes 2, 5, and 11, competition with 10-fold excess cold Sp1;
lanes 3, 6, 9, and 12, competition with a 10-fold excess of the oligonucleotide used for binding.

Sp1 and Chondrocyte Dedifferentiation
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FIG. 11. Protein titration analyzed by gel shift analysis. A, increasing concentrations of nuclear proteins (chondrocyte nuclear protein
(CNP) and fibroblast-like cell nuclear protein (FNP)) were incubated with a constant amount of consensus Sp1 radiolabeled oligonucleotide (88 nM)
B, graph showing the radioactivity in DNA-protein complexes shown in A plotted as a function of protein concentration. C, titration of DNA-protein
binding with increasing concentrations of consensus Sp1 radiolabeled probed with 20 mg of chondrocyte nuclear protein or fibroblast-like nuclear
protein. D, graph showing the radioactivity in DNA-protein complexes shown in C plotted as a function of Sp1 oligonucleotide concentration. E,
autoradiogram of a set of standard dilutions of free Sp1 oligonucleotide analyzed by gel shift analysis. F, plot of radioactivity as a function of Sp1
oligonucleotide concentration shown in E.

set of standard dilutions of free probe demonstrated that 23.2
nM of nuclear protein isolated from chondrocytes dedifferentiated into fibroblast-like cells was present in the reaction (Fig.
11F). Therefore, the amount of nuclear proteins binding to the
Sp1 oligonucleotide was about 2-fold higher in nuclear extracts
isolated from chondrocytes dedifferentiated into fibroblast-like
cells as compared with that of nuclear extracts isolated from
chondrocytes.
Sp1 Activation of the Transcription of COL2A1 PromoterCAT Constructs in Drosophila Schneider Cells—To provide
direct evidence of the role of Sp1 in COL2A1 transcription,
cotransfection experiments were performed with Drosophila

Schneider line L2 cells that lack homologs of Sp1. The construct
E/0.7, which spans bp 2577 to 163 of the COL2A1 promoter,
was co-transfected with either the Sp1 expression plasmid
pPacSp1 or the insertless plasmid pPac0, an identical plasmid
lacking the Sp1 cDNA. The plasmid pSV2-CAT, which contains
the SV40 promoter linked to the CAT reporter gene, or the
plasmid pSV0-CAT, an identical plasmid but lacking the SV40
promoter, was used as positive or negative control, respectively. As shown in Fig. 12, when E/0.7 was transfected alone or
was co-transfected with pSV0-CAT into the Drosophila cells, no
CAT activity was observed. However, when E/0.7 was co-transfected with pPacSp1, the Sp1 expression plasmid, substantial
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CAT activity was detected. When the construct E/0.2, which
spans bp 2131 to 163 was utilized in experiments similar to
those with E/0.7, substantial CAT activity was obtained when
it was co-transfected with the Sp1 expression plasmid
pPacSp1. However, the CAT activity obtained with E/0.2 was
.43% lower than that obtained with E/0.7. The higher CAT
activity produced when E/0.7 was employed may be due to the
presence of two additional Sp1 binding sites in the construct
E/0.7 in comparison with E/0.2.
DISCUSSION

The results reported here revealed qualitative and quantitative
alterations in Sp1 binding activity during chondrocyte dedifferentiation. This conclusion is based on studies carried out
with consensus Sp1 oligonucleotide showing that (i) Sp1 binding activity was present in nuclear extracts from all three cell
types studied; (ii) Sp1 binding was 2–3-fold greater in nuclear
extracts from chondrocytes dedifferentiated into fibroblast-like
cells by passage in monolayer culture on plastic substrate than
in freshly isolated chondrocytes or in chondrocytes allowed to
maintain their phenotype by culture on polyHEMA-coated
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FIG. 12. Effect of Sp1 expression on transcriptional activity of
human COL2A1 promoter constructs transfected into Drosophila Schneider line L2 cells. Drosophilia Schneider line L2 cells were
cultured and transfected by the calcium phosphate precipitation
method using either the pPacSp1 expression plasmid or the insertless
pPac0 and were co-transfected with 5 mg of either E/0.7, a human
COL2A1 promoter construct spanning bp 2577 to 163 linked to the
CAT reporter gene or E/0.2, a human COL2A1 promoter construct
spanning bp 2131 to 163 linked to the CAT reporter gene. All reactions
contained 0.5 mg of the phsp82LacZ, a plasmid containing the Drosophila heat shock protein 82 promoter fused to the lacZ gene to normalize
for variations in transfection efficiencies. The transfected cells were
harvested and CAT activity determined. A, autoradiogram of a representative CAT assay. Drosophila Schneider L2 cells were co-transfected
with either pPacSp1 expression plasmid or the insertless plasmid
pPac0 and COL2A1-CAT E/0.2 and E/0.7 as described under “Experimental Procedures.” The plasmids pSV2-CAT, a plasmid containing the
SV40 early promoter and pSV0-CAT, a plasmid lacking the SV40 early
promoter were used as positive and negative controls, respectively. Ac,
acetylated chloramphenicol; NA, non-acetylated chloramphenicol. B,
autoradiogram of co-transfection of Drosophila Schneider line L2 cells
with pPacSp1 expression plasmid, and pSV2, E/0.2, and E/0.7. Results
from three separate experiments are shown.

dishes; (iii) Sp1 binding was specific, since it was competed by
unlabeled Sp1 and not by AP1; (iv) Sp1 binding was enhanced
by KCl and inhibited by the addition of EDTA; (v) A polyclonal
antibody against Sp1 decreased the binding of Sp1 by 85% in
chondrocytes dedifferentiated into fibroblast-like cells but
caused only a very slight inhibition in freshly isolated chondrocytes or in chondrocytes cultured in suspension on polyHEMA.
Inhibition of Sp1 binding by this polyclonal antibody has been
previously reported in the human granulocyte-macrophage colony-stimulating factor gene promoter (30).
We also observed that culture of chondrocytes under conditions that result in the acquisition of fibroblast-like morphology
resulted in an increase in DNA binding activity to COL2A1
promoter fragments containing Sp1 sites. The increase in binding to the consensus Sp1 oligonucleotide or to the COL2A1
promoter fragment could be due to several reasons. First, there
may be an increased expression of the Sp1 gene. Increase in
Sp1 mRNA has been observed in several organs during mouse
embryo development (31). Second, there may be post-translational mechanisms that are involved. These could be O-linked
glycosylation, protein kinase phosphorylation, or formation of
multimers on single or multiple GC elements. The differential
antibody response observed in the two morphologically different cells types may indicate that the DNA-binding proteins are
different in the two cell types although they have the same
apparent molecular mass. Alternatively, it is possible that
there are subtle differences in the binding of Sp1 oligonucleotide to the same nuclear protein in the two different cell types
that are reflected in the differential antibody response. Quantitative analysis of the amounts of binding proteins employing
DNA-binding protein titration assays demonstrated that 11.88
nM chondrocyte nuclear protein was bound to the consensus
Sp1 oligonucleotide as compared with a 23.2 nM concentration
of fibroblast-like cell nuclear protein. Drosophila Schneider L2
cells that lack homologs of Sp1 have previously been utilized in
co-transfection experiments with the Sp1 expression plasmid
and COL1A1 promoter-CAT constructs to demonstrate a direct
role of Sp1 in the transcription of this gene (32, 33). Higher
stimulation of the COL1A1 promoter activity with CAT constructs containing progressively greater number of Sp1 sites
has previously been reported (33). The activity of the COL2A1
promoter was also significantly increased by Sp1 expressed in
Drosophila Schneider line L2 cells. Higher stimulation of promoter activity was observed when a COL2A1 construct containing a greater number of Sp1 sites was utilized. These results
indicated a direct role of Sp1 in regulation of activity of the
COL2A1 promoter.
Although Sp1 is a ubiquitous transcription factor that is
present in all mammalian cells that have been examined (34),
it has been demonstrated that its binding affinity and transcriptional properties can be altered by different cytokines via
indirect action with co-factors. The role of Sp1 in regulation of
the a2(I) procollagen gene expression has been extensively
studied (35–36). Transforming growth factor-b stimulates the
expression of the a2(I) procollagen gene by increasing the affinity of an Sp1-containing transcriptional complex that is
bound to a sequence in the promoter termed the transforming
growth factor-b-responsive element (35). The same element
also mediates the transcriptional signal of the cytokine tumor
necrosis factor-a that inhibits a2(I) procollagen gene expression (34). Therefore, it is very likely that Sp1 along with other
co-factors may be involved in the regulation of expression of
COL2A1 in chondrocytes.
Our observations of reduced DNA binding of Sp1 in differentiated chondrocytes in comparison with fibroblast-like dedifferentiated chondrocytes can be proposed as a molecular mecha-
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nism that contributes to alterations in expression of COL2A1
and possibly other genes that are differentially regulated in the
two cell types. Further studies to examine the specific sequences within the COL2A1 promoter that interact with Sp1
and to identify the precise mechanism of Sp1 binding will
further our understanding of the mechanisms responsible for
the profound changes in the expression of this gene occurring
during the process of chondrocyte dedifferentiation or in diseases such as osteoarthritis.
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